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ABSTRACT
Glucocorticoids are known to induce osteocyte apoptosis, whereas mechanical loading has been shown to sustain osteocyte viability.
Here we show that mechanical loading in the form of fluid-flow shear stress blocks dexamethasone-induced apoptosis of osteocyte-like
cells (MLO-Y4). Prostaglandin E2 (PGE2), a rapidly induced signaling molecule produced by osteocytes, was shown to be protective
against dexamethasone-induced apoptosis, whereas indomethacin reversed the antiapoptotic effects of shear stress. This protective
effectofshearstresswasmediatedthroughEP2andEP4receptors,leadingtoactivationofthecAMP/proteinkinaseAsignalingpathway.
Activation of phosphatidylinositol 3-kinase, an inhibitor of glycogen synthesis kinase 3, also occurred, leading to the nuclear
translocation of b-catenin, an important signal transducer of the Wnt signaling pathway. Both shear stress and prostaglandin increased
the phosphorylation of glycogen synthesis kinase 3 a/b. Lithium chloride, an activator of the Wnt pathway, also was protective against
glucocorticoid-inducedapoptosis.Whereasitisknownthatmechanicalloadingincreasescyclooxygenase-2andEP2receptorexpression
andprostaglandin production, dexamethasone wasshown to inhibit expression of these components of the prostaglandin pathway and
to reduce b-catenin protein expression. b-catenin siRNA knockdown experiments abrogated the protective effects of PGE2, confirming
the central role of b-catenin in mediating the protection against dexamethasone-induced cell death. Our data support a central role for
PGE2 acting through the cAMP/PKA and b-catenin signaling pathways in the protection of osteocyte apoptosis by fluid-flow shear stress.
 2010 American Society for Bone and Mineral Research.
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Introduction
G
lucocorticoid-induced osteoporosis is the second most
common form of osteoporosis in the United States.
(1)
Individuals treated with glucocorticoids have alterations in bone
remodeling, including an increase in bone resorption and
suppression of bone formation.
(2) Reductions in trabecular bone
mass and trabecular thickness and number are thought to be
responsible for increased bone fragility.
(3–5) These reductions
in bone mass are thought to be due to an increase in both
osteoblastandosteocytecelldeath,orapoptosis.Italsohasbeen
proposed that the increased fragility in these patients compared
with postmenopausal osteoporotic patients is due to changes in
the localized material properties of trabecular bone surrounding
osteocyte lacunae.
(6)
The most abundant bone cell type is the osteocyte (90% to
95% of all bone cells), terminally differentiated osteoblasts
embedded in the mineralized matrix.
(7) Osteocytes are proposed
to coordinate osteoblast and osteoclast activity in response to
mechanical stimuli, translating mechanical strain into biochem-
ical signals that ultimately regulate resorption or formation.
(8,9)
Osteocyte cell death is thought to signal osteoclast recruitment
and activation, leading to bone loss,
(10,11) and recently, this
has been validated in vivo through the use of targeted deletion
of osteocytes.
(12) Osteocyte cell death can occur in association
with age and pathologic conditions such as osteoporosis
and osteoarthritis, leading to increased bone fragility.
(13,14)
Such fragility may be due to loss of the ability of the osteocyte
to sense microdamage and signal to other bone cells for
repair.
(15) Hence osteocyte viability appears to play a
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2657significant role in the maintenance of bone homeostasis and
integrity.
Mechanical loading can maintain or increase bone mass,
whereas unloading or immobilization results in loss of bone
mass. Mechanical loading has been reported to play a role in
maintaining osteocyte viability. Reduced mechanical loading
in vivo increases the number of osteocytes undergoing
apoptosis.
(16) Shear stress inhibits osteocyte apoptosis induced
by low serum,
(17) and dexamethasone-induced osteocyte
apoptosis is attenuated by a form of mechanical loading known
as substrate stretching.
(18) Fluid-flow shear stress (FFSS) is most
likely the form of loading to which the osteocyte is exposed.
(19–21)
Primary osteocytes have been shown to be more sensitive to
shear stress than osteoblasts or fibroblasts and to substrate
stretching compared with hydrostatic compression.
(22) The
biochemical signals induced by mechanical loading responsible
for maintaining osteocyte viability are not known. However, it
has been shown known that fluid-flow shear stress applied to
MLO-Y4 osteocytes results in the release of PGE2, and this leads
to activation of b-catenin signaling.
(23–25) The importance of
b-catenin signaling in the prevention of apoptosis is well
established in several other systems,
(26–28) and this raises the
possibility that activating this pathway in osteocytes could have
a similar protective effect.
This study was undertaken to determine if mechanical
loading in the form of fluid-flow shear stress could inhibit
glucocorticoid-induced osteocyte apoptosis and, if so, to identify
the factor(s) responsible and determine the molecular signaling
mechanisms responsible for this protection. Here we show
that shear stress prevents osteocyte apoptosis induced by
dexamethasone. The protective effect was mediated by
prostaglandin E2 (PGE2) through both the classic cAMP/protein
kinase A (PKA) pathway and crosstalk between the phospha-
tidylinositol 3-kinase (PI3K)/Akt and b-catenin signaling path-
ways in osteocyte-like MLO-Y4 cells. Dexamethasone inhibited
b-catenin stabilization and the expression of its target genes in
addition to its inhibitory effects on cyclooxygenase-2 (COX-2)
and EP2 receptor gene expression and PGE2 production.
This study may have important implications for the treatment
of glucocorticoid-induced osteoporosis because the pathways
used byshearstress containmolecular elementsthat couldserve
as therapeutic targets.
Materials and Methods
Cell culture
The osteocyte-like MLO-Y4 cell line, derived from murine long
bone,
(29) was used as an in vitro osteocyte model. MLO-Y4 cells
wereculturedoncollagen typeI–coated platesorglass slides(rat
tail collagen type I, 0.15mg/mL) in a-MEM without phenol red
supplemented with 2.5 % fetal bovine serum (FBS), 2.5% calf
serum (CS) in a 5% CO2 incubator at 378C.
Fluid-flow shear-stress (FFSS) experiment
MLO-Y4 cells were plated on glass slides coated with type I
collagen at a density of 3 10
4 cells/cm
2 and were used at
approximately 80% confluence. Cells were subjected to 16 dyn/
cm
2 steady laminar FFSS for 2hours in the presence or absence
of 1mM indomethacin. After incubation for 2 hours, 1mM
dexamethasone (Sigma-Aldrich, St Louis, MO, USA) was added
for an additional 6hours to induce apoptosis. Pretreatment was
performed with indomethacin 12hours before application of
FFSS, during FFSS, and during the 2-hour postincubation time.
Cells were fixed with neutral buffered formalin and stained with
DAPI. Cells that showed nuclear condensation, blebbing, and
fragmentation were counted as apoptotic cells. Four fields per
each slide and 500 cells were counted from each field under the
microscope (n¼3).
Quantification of apoptotic cells
Apoptotic cells were quantified by nuclear fragmentation assay
and trypan blue exclusion assay, as described previously.
(30)
MLO-Y4 cells were plated at 1 10
4 cells/cm
2 on a collagen-
coated 48-well plate, with three to four wells used for each
experimental condition. Representative examples of each assay
are shown. Cells were pretreated with varying concentrations of
PGE2 (Sigma-Aldrich), 5mM butaprost, 5mM sulprostone, 5mM
PGE1 alcohol (Cayman Chemical, Ann Arbor, MI, USA), 100mM
8-bromo-cAMP (Sigma-Aldrich), or 10mM LiCl for 1 hour, follow-
ed by treatment with 1mM of dexamethasone for 6 hours. If
necessary, cells were pretreated with 5mM of EP2 antagonist
AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid; Cay-
man Chemical), 5mM of EP4 antagonist CP-147499 (kindly
provided by Dr Lydia Pan, Pfizer, Inc., Groton, CT, USA), 5mMo f
H89 (isobutylmethylxanthine; Sigma-Aldrich), or 1mM of wort-
mannin (Sigma-Aldrich) for 0.5 to 1 hour prior to addition of
PGE2. For the nuclear fragmentation assay, MLO-Y4 cells were
stained with DAPI. Cells exhibiting chromatin condensation and
nuclear fragmentation were detected by fluorescence micro-
scopy. A total of 500 cells were examined for each experimental
condition by systematic random sampling. The percentage of
MLO-Y4 cells stained with trypan blue has been shown previ-
ously to correlate with that of apoptotic cells.
(30) For the trypan
blue assay, after treatment, adherent cells released by trypsin-
EDTA were combined with nonadherent cells and collected by
centrifugation. Then 0.04% trypan blue (Sigma-Aldrich) was
added, and cells exhibiting both nuclear and cytoplasmic stain-
ing were determined using a hemocytometer under a light
microscope. A total of 100 cells per each experimental condition
were counted.
Western blot analysis
For Western blot studies, MLO-Y4 cells were grown on type I
collagen–coated 6-well plates or glass slides at 1 10
4 cells/cm
2.
At the various indicated time points, cells were treated with (1)
16 dyn/cm
2 FFSS or (2) incubated with 5mM of PGE2 in the
presence or absence of preincubation with wortmannin or H89
for 0.5 to 1 hour. As a positive control, cells were treated with
10mMofLiCl,whichinhibitsglycogensynthesiskinase3(GSK-3).
After each treatment, the cells were washed with cold PBS twice
and lysed with RIPA buffer including proteinase and phospha-
tase inhibitors (Sigma-Aldrich). The lysates were sheared using a
22-gauge needle, centrifuged at 12,000rpm for 10 minutes at
2658 Journal of Bone and Mineral Research KITASE ET AL.48C, and the supernatants were collected. The cell lysate and
sample buffer were mixed and boiled for 5 minutes before
loading on the gel. Proteins (5mg) were separated by SDS-PAGE
under constant voltage (160V) and were transferred electro-
phoretically to a nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA)ata60-Vconstantcurrentfor2hours.Themembraneswere
blocked in a blocking solution overnight at 48C and incubated
with the primary antibody [anti-phospho-GSK3a/b (1:1000; R&D
Systems, Minneapolis, MN, USA), anti-GSK-3a, anti-GSK-3b
(1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-b-
catenin (1:4000; Abcam, Cambridge, MA, USA), or anti-actin
(1:4000; Sigma-Aldrich)] overnight at 48C. The blots were in-
cubated with a horseradish peroxidase–linked secondary anti-
body (antirabbit/antimouse IgG; Boehringer, Mannheim,
Germany) for 2 hours at a room temperature. Afterwards, the
immunoblots were visualized with a chemiluminescence detec-
tion kit (Pierce, Rockford, IL, USA). The semiquantitative analysis
of band intensity was performed using an EPSON scanner
and NIH Image 1.63 software. The intensity of GSK-3a/b total
protein and actin was used for normalization of phosphorylated
GSK-3a/b.
Immunofluorescence
MLO-Y4 cells were grown on type I collagen–coated glass slides
at 1 10
4 cells/cm
2 and then treated with 16 dyn/cm
2 FFSS or
5mM of PGE2 for 2 hours. As a positive control, cells were treated
with 10mM of LiCl. After each treatment, the cells were washed
with cold PBS twice, fixed in cold 4% paraformaldehyde–0.02%
Triton for 5 minutes, and washed three times with PBS. The slides
were blocked with a blocking solution overnight at 48C and
incubated with the primary antibody against b-catenin (E-17)
(1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
overnight at 48C in a humidified chamber. After washing with
PBS three times, a Cy3-labeled secondary donkey antigoat IgG
antibody (1:200; Jackson ImmunoResearch, West Grove, PA, USA)
was incubated on the sections for 1 hour at room temperature
and then washed with PBS six times. Coverslips were mounted
with mounting medium (9:1 glycerol/PBS plus 5% N-propyl
gallate). Digital images were acquired with an optronics camera
and analyzed with imager software. As negative controls, the
primary antibody was omitted from the staining procedure.
mRNA isolation and microarray analysis
Gene array analysis was performed on MLO-Y4 cells treated with
dexamethasone for 4 and 24 hours. After each treatment, total
RNA was isolated from cells using TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA). cDNA was made and denatured, labeled,
and then hybridized to the mouse genome 430A 2.0 array
chips (Affymetrix, Santa Clara, CA, USA). A set of microarray
hybridization experiments was performed according to the
manufacturer’s protocols. After hybridization, microarray experi-
ments were analyzed for expression changes based on the GCOS
package with no statistical evaluation except the default with
one array per condition and present and absent calls of the
software.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
In addition, 1 10
4 cells/cm
2 of MLO-Y4 cells were incubated in
100-mm tissue culture plates in the presence or absence of 1mM
of dexamethasone for 6, 24, and 48 hours. After treatment, total
RNA was extracted using TRIzol Reagent (Invitrogen) and reverse
transcribed at 488C for 30 minutes using a Taqman Reverse
Transcription Reagents Kit (Applied Biosystems, Austin, TX, USA)
in a final volume of 20mL. Two microliters of cDNA were used
as template for amplification by PCR. Taqman real-time
quantitative PCR (qPCR) analysis for COX-2 (Applied Biosystems,
Cat. No. Mm01307334_g1), EP2 receptor (Applied Biosystems,
Cat. No. Mm00436051_m1), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Applied Biosystems, Cat. No. 4308313)
was performed as described by the manufacturer’s protocol
using premade Taqman gene expression assays (Applied
Biosystems). GAPDH expression levels were used as reference
for normalization.
b-Catenin siRNA experiments
MLO-Y4 cells were plated at 1 10
4 cells/cm
2 on collagen-
coated6-wellplates1daypriortothestartoftheb-cateninsiRNA
experiment. Cells were transiently transfected with siRNA
oligonucleotides (50 nM) using Oligofectamine Reagent (Invitro-
gen). b-Catenin siRNA and negative-control RNA were purchased
from Ambion (Austin, TX, USA). Reduction of b-catenin mRNA
levels was measured by qPCR 24 hours after transfection, and
protein levels were analyzed by Western blotting 48 hours after
transfection. At 48 hours after transfection, the cells were
exposed to 5mM of PGE2 for 2 hours, followed by 1mMo f
dexamethasonefor6hours.Aftertreatment,apoptoticcellswere
determined by trypan blue staining, as described earlier. A total
of 100 cells per each experimental condition were counted.
Enzyme-linked immunosorbent assay (ELISA)
MLO-Y4 cells were incubated in 48-well plates at 1 10
4 cells/
0.3mL of medium per well in the presence or absence of 1mM
dexamethasone for 24 and 48hours. After treatment, super-
natants were collected, and the concentrations of soluble PGE2
were assayed using a commercially available kit (Prostaglandin
E2 EIA, Cayman Chemical), according to manufacturer’s protocols.
Statistical analysis
Alldataarepresentedasmean SDandn¼3to4.Thestatistical
significance of difference between mean values was determined
by one-way ANOVA followed by Tukey-Kramer post hoc analysis.
All comparisons at p<.05 were considered significant.
Results
FFSS is protective against dexamethasone-induced
osteocyte apoptosis owing to a soluble factor and
indomethacin abrogates the protective effect of FFSS
Since mechanical loading has been reported to play an
important role in maintaining osteocyte viability, we performed
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examine the effect of FFSS on apoptosis in MLO-Y4 osteocyte-
like cells (Table 1). Treatment of MLO-Y4 cells with 1mMo f
dexamethasone for 6 hours resulted in an approximately 50%
increase in the number of apoptotic cells measured by either
nuclear fragmentation or trypan blue exclusion. Two hours of
16 dyn/cm
2 steady FFSS effectively protected against the
dexamethasone-induced apoptosis. Since FFSS is well known
to rapidly induce release of prostaglandins from osteocytes
(31)
and MLO-Y4 cells,
(32) weexaminedthe effects of indomethacin, a
potent inhibitor of prostaglandin synthesis. In the presence of
1mM of indomethacin, present during the entire experimental
time, the protective effects of FFSS were significantly abrogated.
In addition, harvested conditioned media from cells subjected to
FFSS blocked dexamethasone-inducedapoptosis, indicating that
a soluble factor produced by MLO-Y4 cells might be mediating
the protective effect of FFSS (Table 1).
Exogenous addition of PGE2 protects against
dexamethasone-induced MLO-Y4 cell apoptosis
Since indomethacin effectively abrogated the protective effect
of FFSS on dexamethasone-induced apoptosis (Table 1), we next
examined whether exogenous addition of PGE2 would have the
same antiapoptotic protective effect using both the nuclear
fragmentation assay and trypan blue exclusion assay and to
determine the optimal dose response (Table 2). Both assays
revealed that PGE2 (10
 5 to 10
 8 M) was able to prevent or
reduce MLO-Y4 cell apoptosis induced by dexamethasone.
Taken together, these data support the hypothesis that PGE2
release in response to FFSS is protective against glucocorticoid-
induced osteocyte apoptosis.
The protective effect of PGE2 is mediated through EP2
and EP4 receptors
Since PGE2 was able to protect against the effects of
dexamethasone, it was logical to ask whether dexamethasone
affected intracellular stores of PGE2 in MLO-Y4 cells and whether
(which) PGE2 receptors mediated the PGE2 protection. As shown
in Fig. 1A, MLO-Y4 cells treated with dexamethasone for 24 and
48 hours produced 7.5 (control 1854 57, dexamethasone
246 23
apg/10
4cells)and9(control1174 67,dexamethasone
131 4
apg/10
4cells) fold less PGE2, respectively, comparedwith
control, as determined by ELISA (p<.001 versus each control).
Next, we determined which receptor is responsible for the
protection ofPGE2againstosteocyte apoptosis. PGE2isknownto
exert its effects through four different types of receptors, EP1,
EP2, EP3, and EP4.
(33) Therefore, we examined the effect of
pharmacologic activators and inhibitors of EP receptors on
osteocyte cell death (Fig. 1B–D). Addition of 5mM of butaprost,
an EP2 agonist, prevents dexamethasone-induced cell death to a
similar extent as 5mM of PGE2. However, 5mM of sulprostone, an
EP1/EP3 agonist, did not inhibit osteocyte cell death. Similarly,
5mM of PGE1 alcohol, another EP3/EP4 receptor agonist, did not
statistically inhibit cell death (Fig. 1B). These data suggest that
the protective effect of PGE2 is mediated through EP2 and EP4,
but not EP1 and EP3 receptors. To further verify the involvement
of EP2 and EP4 receptors in the protective function of PGE2,
selective antagonists against each receptor were tested. Five
micromolar AH6809, an EP2 selective antagonist, partially but
significantly reversed the protective effect of PGE2 (Fig. 1B). Five
micromolar CP-147499, an EP4 selective antagonist (Fig. 1D), was
less effective than the EP2 selective antagonist AH6809 (Fig. 1C).
The cAMP/PKA pathway partially mediates the protective
effect of PGE2
EP2 and EP4 receptors are coupled to trimeric G-proteins, and
one pathway they can act through is by activation of adenylyl
cyclase, which increases intracellular cAMP and results in the
Table 1. Effect of Dexamethasone, FFSS, PGE2, and
Indomethacin and Fluid Flow Conditioned Media (FFCM) on
Apoptosis of MLO-Y4 Osteocytes
Nuclear fragmentation (apotosis %)
Control 8.75 0.80
Dexamethasone 12.78 0.45
a
FFSSþdexamethasone 9.03 0.85
b
Indo/FFSS/dexamethasone 12.99 0.35
a
Trypan blue exclusion (dead cell %)
Control 7.24 0.64
Dexamethasone 11.37 1.24
a
FFCMþdexamethasone 7.13 1.31
b
PGE2þdexamethasone 9.31 0.60
b
ap<.01 versus control.
bp<.01 versus dexamethasone.
Table 2. PGE2 Dose-Dependent Decrease in Dexamethasone-Induced MLO-Y4 Cell Apoptosis
Condition Nuclear fragmentation (% apoptotic cells) Trypan blue (% dead cells)
Control 11.45 1.34 8.48 0.63
Dexamethasone 18 1.71
a 17.22 2.66
a
Dexamethasoneþ10
 8 PGE2 15.4 0.35
b,,c 13.80 1.14
a,,c
Dexamethasoneþ10
 7 PGE2 15.13 0.31
b,,c 11.77 0.63
a,,d
Dexamethasoneþ10
 6 PGE2 10.67 0.92
d 9.75 2.53
d
Dexamethasoneþ10
 5 PGE2 nd 9.11 1.01
d
ap<.01 versus control.
bp<.05 versus control.
  cp<.05 versus dexamethasone.
dp<.01 versus dexamethasone.
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whether an increase in intracellular cAMP would protect MLO-Y4
cells against dexamethasone-induced cell death (Fig. 2). As
shown in Fig. 2A, 100mM of 8Br-cAMP was as protective as PGE2,
and the PKA inhibitor H89 at 5mM significantly blocked the
protective effect of PGE2 (Fig. 2B).
The protective effect of PGE2 is also mediated via the
PI3K/Akt/GSK-3/b-catenin pathway
PGE2 has been shown to activate the PI3K/Akt signaling
pathway,
(34) stimulate the growth and survival of colon cancer
cells through crosstalk with the b-catenin pathway,
(35,36) and
activate b-catenin signaling in MLO-Y4 osteocyte-like cells.
(24,25)
In addition, this pathway is activated in response to FFSS in MLO-
Y4 osteocyte-like cells.
(24,25) Therefore, we sought to determine if
PI3K also might be involved in the protective effects of PGE2
against dexamethasone-induced apoptosis. The inhibition of
PI3K by wortmanin was able to reverse the protective effects of
PGE2 on dexamethasone-induced apoptosis (Fig. 3A). Next, we
examined the effect of lithium chloride (LiCl) on MLO-Y4 cell
death induced by dexamethasone because LiCl is well known to
activate the b-catenin pathway through the inhibition of GSK-
3a/b kinase activity. In fact, 10mM of LiCl showed highly
significant protective effects, similar to PGE2, against dexa-
methasone-induced MLO-Y4 cell death (Fig. 3B). This suggested
that the PI3K and b-catenin pathway mediate the protective
effects of PGE2.
Next, we tested whether both FFSS and PGE2 could lead to
increased phosphorylation/inactivation of GSK-3a/b (Fig. 4).
In fact, 5mM of PGE2 effectively increased the phosphorylation
of GSK-3a and GSK-3b by approximately twofold at about
45minutes (Fig. 4A). FFSS at 16 dyn/cm
2 increased GSK-3a/b
phosphorylation similar to PGE2. Western blot analysis revealed
that FFSS was able to increase the phosphorylation of both GSK-
Fig. 1. (A) The effects of dexamethasone on PGE2 production by MLO-Y4 cells. PGE2 concentration in MLO-Y4 cells was measured by EIA (Cayman
Chemicals).
 p<.05. (B–D) The effects of PGE2 on dexamethasone-induced apoptosis are mediated through the EP2 and EP4 receptors. (B) MLO-Y4 cells
were pretreated with 5mM of PGE2,5mM butaprost (EP2 agonist), 5mM of PGE1 alcohol (EP3/EP4 agonist), or 5mM of sulprostone (EP1/EP3 agonist) for
1 hour followed by 1mM of dexamethasone for 6 hours. Treatment with butaprost significantly inhibited dexamethasone-induced cell death to a similar
extent as PGE2. To further confirm the EP receptor mediating the effect of PGE2, MLO-Y4 cells were pretreated with AH6809, an EP2-selective antagonist
(C),orCP-147499,anEP4selectiveantagonist(D),for30minutes,followedbytreatmentwith5mMofPGE2for1hour.Thecellsthenwereexposedto1mM
of dexamethasone for 6 hours. AH6809 reversed the protective effect of PGE2 (C), whereas CP-147499 only reversed the protective effect of PGE2 slightly
(D). Panels A–C:
  p<.01 and
 p<.05 versus control;
##p<.01 versus dexamethasone alone and
þp<.05 versus dexamethasone with pretreatment of
PGE2.
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45minutes compared with the negative control (Fig. 4B). Both
FFSS and PGE2 showed similar kinetics, reaching a peak effect at
45minutes, the same time point showing maximal phosphor-
ylation induced by FFSS.
To validate that PI3K is upstream of GSK-3b inhibition, cells
exposed to either PGE2 or to FFSS were treated with the PI3K
inhibitor wortmannin. The inhibition of PI3K reversed the
protective effects of PGE2 on dexamethasone-induced apoptosis
(Fig. 3A). Wortmannin at 10
 6 to 10
 7 M inhibited the
phosphorylation of GSK-3 induced by 5mM of PGE2 dose-
dependently, with maximum inhibition at 10
 6 M (Fig. 5A).
Similar to PGE2, the phosphorylation of GSK-3a/b induced by
FFSS also was blocked by addition of 1mM of wortmannin
(Fig. 5B). We have shown previously that PGE2 increases
intracellular cAMP and activates PKA in MLO-Y4 cells.
(32) PKA
kinase has been shown to mediate phosphorylation of GSK-3a/
b.
(34,37,38) The PKA inhibitor H89 at 5mM completely blocked PKA
activity in MLO-Y4 cells
(39) but did not inhibit the phosphoryla-
tion of GSK-3a/b (Fig. 5C). This suggests that the effects of PGE2
on GSK phosphorylation are mediated through PI3K but not
PKA activity.
Fig. 2. The cAMP/PKA pathway partially mediates the protective effect of PGE2 on dexamethasone-induced cell death. To determine the role of this
pathway in the protective effects of PGE2, MLO-Y4 cells were pretreated with 5mM of PGE2 or 100mM of 8Br-cAMP for 1 hour, followed by 1mMo f
dexamethasone for 6hours. (A) Treatment with 8Br-cAMP significantly inhibited dexamethasone-induced cell death similar to PGE2. MLO-Y4 cells were
pretreated with H89, a PKA inhibitor, for 30minutes, followed by treatment with 5mM of PGE2 for 1 hour. The cells then were exposed to 1mMo f
dexamethasone for 6hours. (B) The PKA inhibitor H89 partially antagonizes the protective effect of PGE2.
  p<.01 versus control;
##p<.01 versus
dexamethasone alone; and
þþp<.01 versus dexamethasone with pretreatment of PGE2.
Fig. 3. The PI3K/Akt/b-catenin pathway is involved in PGE2 protection against dexamethasone-induced apoptosis. (A) The protective effects of PGE2
against dexamethasone-induced apoptosis are abrogated by wortmanin (designatedW), an inhibitor of PI3K. Wortmannin at 10
 6 M was added.
  p<.01
versus control and
##p<0.01 versus dexamethasone alone. (B) LiCl, known to activate the b-catenin pathway, protects against dexamethasone-induced
cell death. MLO-Y4 cells were pretreated with 5mM of PGE2 or 10mM of LiCl for 1 hour, followed by addition of 1mM of dexamethasone for 6 hours.
Treatment with LiCl inhibited dexamethasone-induced cell death comparable with PGE2.
  p<.01 versus control and
##p<.01 versus dexamethasone
alone.
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whereas dexamethasone inhibits stabilization of
b-catenin
Both FFSS and PGE2 induced b-catenin nuclear translocation,
similar to LiCl (positive control), as shown in Fig. 6. Clearly,
nuclear translocation of b-catenin occurs in MLO-Y4 cells
subjected to either FFSS or to PGE2, as indicated by the bright
nuclear staining (Fig. 6A). This shows that both PGE2 and FFSS
target b-catenin to the nucleus. Next, siRNA knockdown
experiments were performed using siRNA to b-catenin. Western
blottingshowedthatb-cateninproteinwassignificantlyreduced
fourfoldat48hoursaftertransfection(Fig.6B).qPCR showedthat
b-catenin mRNA decreased 86% compared with the RISC-free
negativecontrolat24hoursaftertransfection(Fig.6B).Cellswere
transiently transfected with siRNA oligonucleotides targeting
b-catenin and RISC-free negative control for 48hours, followed
by incubation with 5mM of PGE2 for 2hours (Fig. 6C). The cells
then were exposed to 1mM of dexamethasone for 6hours.
b-catenin silencer siRNA reversed the protective effect of PGE2,
whereas the RISC-free negative control had no significant effect.
Transfection of siRNA oligonucleotides alone had no significant
effect. Vehicle, siRNA alone, or RISC alone had no significant
effect. Knockdown of b-catenin blocked the protective effect of
PGE2 against the dexamethasone-induced apoptosis.
Next, Western blot analysis of b-catenin in MLO-Y4 cells
treated with 10mM LiCl, 5mM PGE2, and FFSS at 16 dyn/cm
2 was
performed to determine if these treatments altered protein
levels. No major changeintotal protein expression wasobserved
compared with control (data not shown). However, dexametha-
sone decreased the amount of b-catenin protein approximately
40% compared with control (Fig. 6D).
To determine if dexamethasone has an effect on upstream
mediators of the b-catenin pathway, we investigated the effects
of dexamethasone on expression of PGE2 synthase (COX-2) and
the EP receptors (Table 3). The relative expression of mRNA for
the cyclooxygenase isoenzymes COX-1 and -2 and the PGE2
receptors EP1 to EP4 in MLO-Y4 cells treated with 1mMo f
dexamethasone for 4 and 24hours using cDNA microarray
analysis is shown in Table 3A. COX-2 mRNA was inhibited by
dexamethasone treatment, 2- and 15-fold lower at 4 and
24hours, respectively, compared with control. Dexamthasone
Fig. 4. PGE2 and FFSS similarly increase the phosphorylation of GSK-3a and -b, a mediator of b-catenin activation. Western blot analysis and quantitation
ofphospho-GSK-3aand-bwasperformedinMLO-Y4cellswithexogenousadditionofPGE2andwithexposuretoFFSS.(A)MLO-Y4cellstreatedwith5mM
ofPGE2 alsoshoweda maximalinductionofphosphorylation of a andb at 45minutes. After2hours of16 dyn/cm
2 FFSS, thecell lysateswereharvestedat
15, 30 45, 60, and 120minutes. (B) FFSS also induced phosphorylation of both a and b, with the highest induction being at 45minutes after cessation of
shear stress. Semiquantitative analysis of band intensity was performed using the intensity of total GSK-3a and -b bands for normalization of the
phosphorylatedbands.BothFFSSandPGE2increasedthephosphorylationofbothofGSK-3aand-bmaximallyat45minutesafterapplicationofstimulus.
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other three receptors, approximately threefold lower than
control at 24hours. The positive controls in this experiment
were GILZ (glucocorticoid-induced leucine zipper) and FKBP51
(FK-506-binding protein), which have been reported previously
to be increased by glucocorticoids.
(40,41) Validation of the gene
array approach by qRT-PCR showed mRNA expression of COX-2
and EP2 receptor in MLO-Y4 cells to be significantly reduced
by dexamethasone at each time point (6, 24, and 48hours)
(Table 3B).
Discussion
We describe for the first time a mechanism that connects fluid-
flow shear stress (FFSS)–induced release of PGE2 with down-
stream signaling pathways that protect osteocytes against
dexamethasone-induced apoptosis. Shear stress was shown to
prevent apoptosis induced by dexamethasone in MLO-Y4
osteocyte-like cells by inducing PGE2 release and its subsequent
binding to EP2 and EP4 receptors activating both the cAMP/PKA
and PI3K/Akt/GSK-3a/b/b-catenin pathways. Dexamethasone
inhibited b-catenin stabilization and the expression of down-
stream target genes in addition to inhibiting genes responsible
for prostaglandin production and signaling, COX-2 and the EP2
receptor. An important function for prostaglandin has been
identified, which is as an antiapoptotic agent for osteocytes that
provides protection against glucocorticoid-induced apoptosis.
The results of our studies are illustrated in the model shown
in Fig. 7.
The osteocyte lacunocanalicular system is filled with bone
fluid, and it is hypothesized that it is the movement of this fluid
that maintains osteocyte viability by preventing hypoxia in these
cells deeply embedded in a mineralized matrix.
(42,43) In addition
to maintaining osteocyte viability, movement of the bone fluid
most likely induces shear stress on the cell membrane of the
cell body and along the dendritic process traveling through
canaliculi.
(44) This shear stress is thought to be the means
whereby the cells sense load on the skeleton.
(45) Mechanical
loading is well known to maintain osteocyte viability, and
physiologic levels of mechanical loading were shown to prevent
apoptosis of osteocytes in vivo.
(17) Alternatively, reduced
mechanical loading increases the number of apoptotic osteo-
cytes.
(16) In vitro, mechanical loading reduces the number of
osteocytes undergoing apoptosis induced by serum starva-
tion
(46) and by dexamethasone,
(18) but the molecular mechan-
isms have not been reported. These studies suggest that one
potential agent produced by osteocytes in response to
mechanical loading is PGE2, and our data suggest that it
functions as an osteocyte viability factor.
Evidence isemergingthat PGE2canfunctionas eithera pro-or
an antiapoptotic factor. It has been reported that PGE2 can
function as a protective factor in several types of cells, such as
epithelial cells, dendritic cells, and neurons.
(47–49) In bone cells,
PGE2 was shown to exert an antiapoptotic effect on bone
marrow stromal cells and periosteal cells, thereby increasing
Fig. 5. The PI3K inhibitor wortmannin prevents the phosphorylation of GSK-3a and -b by PGE2 and FFSS, whereas the PKA inhibitor H89 had no effect.
(A) Western blot analysis of phospho-GSK-3 in MLO-Y4 cells pretreated with varying concentrations of wortmannin for 30 minutes before application
of 5mM of PGE2 for 45minutes. Wortmannin at 10
 6 and 10
 7 M dramatically inhibited GSK-3a and -b phosphorylation, as induced by PGE2.
(B) Wortmannin prevents the phosphorylation of GSK-3 by FFSS, similar to PGE2. MLO-Y4 cells were pretreated with 1mM of wortmannin for 1 hour
beforebeingsubjectedtoFFSSof16dyn/cm
2for45minutes.LiClwasusedasapositivecontrol.(C)H89hadnoeffectonPGE2-inducedphosphorylationof
GSK-3a and -b.
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(49,50)
There are also opposing reports showing that PGE2 can induce
apoptosis in several types of cells, such as articular chondro-
cytes.
(51) Thus the effect of PGE2 in cell survival or apoptosis may
depend on cell and/or tissue type.
PGE2 can bind to four subtypes of cell surface receptors,
designated EP1 through EP4.
(33) EP2 and EP4 receptors activate
andsignalthroughadenylylcyclase,EP1activatesphospholipase
C, and EP3 actually inhibits adenylyl cyclase.
(33,52,53) By using
agonists and antagonists to each receptor, we observed that the
effects of PGE2 were mediated mainly through the EP2 receptor,
with less activation of the EP4 receptor. These same receptors
have been shown to mediate the effects of PGE2 on survival of
bone marrow stromal cells and periosteal cells.
(49,50) Activated
adenylate cyclase via EP2 and EP4 receptors increases cAMP,
leading to activation of PKA.
(53) In this study, the use of a cAMP
analogue, 8Br-cAMP, and a PKA inhibitor, H89, showed that the
cAMP/PKA pathway is involved in the protective effects of PGE2.
This suggests that activation of the cAMP/PKA pathway also
plays a critical role in maintaining osteocyte viability.
However, in this study, the protective effects of PGE2 were not
completely mediated through the activation of the cAMP/PKA
signaling cascade. PGE2 also can activate multiple signaling
cascades, including the MAPK, NF-kB, and PI3K/Akt pathways,
(54–
56) and recently, it has been reported to crosstalk with and
activate the b-catenin signaling pathway, well known to play an
important role in cell survival.
(35) In colon cancer, PGE2 activates
the EP2 receptor, leading to activation of PI3K and the protein
kinase Akt by free G-protein bg subunits and the direct
association of the G-protein as subunit with axin. This leads to
Fig. 6. LiCl, FFSS, and PGE2 stabilize and activate the nuclear translocation of b-catenin, whereas dexamethasone reduces b-catenin protein expression.
Cells were treated with 10mM of LiCl, 16 dyn/cm
2 of FFSS, or 5mM of PGE2 for 2 hours, followed by fixation, and then were subjected to
immunofluorescent immunostaining using antibody against b-catenin, as described under ‘‘Materials and Methods.’’ (A) FFSS and PGE2 treatment
induces b-catenin stabilization and nuclear translocation comparable with that of LiCl. (B) Transfection of MLO-Y4 cells with b-catenin siRNA reduced both
mRNA and protein levels by 75% to 80%. (C) b-Catenin silencer siRNA reversed the protective effect of PGE2, whereas RISC-free negative control failed to
block the protective effect. Cells were transiently transfected with siRNA oligonucleotides targeting b-catenin and RISC-free negative control for 48 hours,
followedby5mMofPGE2for2hours.Thecellsthenwereexposedto1mMofdexamethasonefor6hours.(D)Westernblotanalysisofb-catenininMLO-Y4
cellstreatedwith10
 6Mofdexamethasonewasperformed.Areductioninb-cateninproteinwasobserved.
 p<.05versuscontrol(designatedC).
#p<.05
versus dexamethasone alone.
  p<.05 versus control or versus dexamethasone/PGE2.
##p<.05 versus dexamethasone/PGE2/siRNA or versus dex-
amethasone alone.
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accumulation responsible for colon cancer cell viability.
(35) The
protective effects of PGE2 in neurons also have been reported to
occur by transactivation of b-catenin.
(57)
In this study, we observed that activation of the b-catenin
pathway by LiCl resulted in the rescue of osteocytes from cell
death. The use of the PI3K inhibitor wortmannin also prevented
the phosphorylation of GSK-3, partially abrogating the anti-
apoptotic effects of PGE2. Together these data indicate that the
PI3K/Akt/GSK-3/b-catenin pathways also play a key role in PGE2-
mediated osteocyte survival. Similar observations were made
with regard to the antiapoptotic actions of PGE2 in neurons.
(57)
Therefore, the protective effects of PGE2 appear to be mediated
through multiple signaling cascades.
PreviousstudiesintransgenicmicecarryingtheG171VorHBM
(high-bone-mass) mutation in Lrp5 have shown decreased
osteoblast and osteocyte apoptosis in the bones of these
mice.
(58) The Lrp5 coreceptor that binds Wnt and regulates the
Wnt/b-catenin signaling pathway is absolutely required for new
bone formation in response to mechanical loading.
(59) The data
presented here extend these in vivo observations by demon-
strating that a normal function of b-catenin signaling in
osteocytes is maintenance of cell viability. Our data further
illustrate the complex and multiple interactions (Fig. 7) that exist
within bone cells between various signaling pathways and that
understanding osteocyte function will require a thorough
knowledge of how these pathways are coordinately regulated
in response to various perturbations.
In summary, PGE2 produced by osteocytes in response to
mechanical strain shows a protective function against gluco-
corticoid through activation of several signaling cascades.
Since osteocyte cell death is a potential mediator of targeted
osteoclast recruitment, preservation of osteocyte viability is
another areaofinvestigation fortheprevention orattenuation of
primary and secondary osteoporosis and other bone-related
diseases. It will be important to determine if increased
mechanical loading alone or in combination with therapeutics
will reduce or prevent the detrimental effects of glucocorticoid
on osteocyte viability and bone integrity.
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Table 3A. Dexamethasone Inhibits the Expression of COX-2
and the EP2 Receptor Genes and Downstream Targets of the
b-Catenin Pathway
Gene 4 hours 24 hours
Ptgs1 (COX-1) 0.82 0.66
Ptgs2 (COX-2) 0.43 0.06
a
Ptger1 (EP1 receptor) 0.80 1.08
Ptger2 (EP2 receptor) 0.80 0.34
a
Ptger3 (EP3 receptor) 0.89 0.84
Ptger4 (EP4 receptor) 0.74 0.92
Wisp1 1.03 0.52
Vegf 0.73 0.42
Connexin 43 1.01 0.53
Gilz 6.83 4.60
Fkbp51 6.13 6.19
Note: MLO-Y4 cells were treated with 1mM dexamethasone for 4 or
24hours, and mRNA levels measured using mouse genome 430A 2.0
array chips according to the manufacturer’s protocols. Expression is
shown as fold induction based on the expression level in control,
nontreated MLO-Y4 cells at 4 and 24hours, respectively.
aSignificant changes confirmed by real-time quantitative PCR.
Table 3B. Real-Time PCR Data Showing That Both COX-2 and
EP2 Are Reduced with Dexamethasone Treatment Over 6, 24,
and 48 Hours
COX-2 relative
to control (Ctrl)
EP2 receptor relative
to control (Ctrl)
Ctrl—6h 1.0 (0.88–1.14) 1.0 (0.64–1.57)
Dex—6h 0.26 (0.19–0.35) 0.11 (0.08–0.16)
Ctrl—24h 1.0 (0.85–1.18) 1.0 (0.63–1.58)
Dex—24h 0.19 (0.14–0.24) 0.23 (0.17–0.31)
Ctrl—48h 1.0 (0.84–1.18) 1.0 (0.79–1.27)
Dex—48h 0.04 (0.03–0.05) 0.22 (0.18–0.26)
Fig. 7. A diagram showing the means whereby mechanical loading (e)
prevents apoptosis. Mechanical loading, in the form of FFSS, induces the
releaseofprostaglandin(PGE2)throughconnexin43hemichannels(Cx43
HCs), as shown previously by Cherian and colleagues
(32) to have both
autocrine and paracrine effects through EP2 and EP4 receptors. These
receptors not only signal through the traditional cAMP/PKA pathway to
reduce apoptosis but also signal through the PI3k/Akt/GSK-3/b-catenin
pathway.Lithiumchloride(LiCl)alsoblocksapoptosis.Thesamemechan-
ism and pathways were shown to be responsible for the transcription of
Cx43 and increased gap junction function.
(25) For additional information
on the potential for crosstalk between these two pathways and role in
bone cell function, see the review by Bonewald and Johnson.
(60)
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